Last reviewed · How we verify
Stem Cells Lenses
Stem Cells Lenses is a Small molecule drug developed by Guangdong ProCapZoom Biosciences Co., Ltd.. It is currently in Phase 1 development.
Stem cells, specifically equine umbilical cord mesenchymal stem cells, are being studied in clinical trials for various conditions, including vaginal atrophy, lichen sclerosus, corneal disease, pterygium, and myopia. The mechanism of action of these stem cells is classified as somatic cell supplemental therapy, but the exact modality is unknown.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Stem Cells Lenses |
|---|---|
| Sponsor | Guangdong ProCapZoom Biosciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Corneal Epithelium Defect
- Subconjunctival Hemorrhage
- Conjunctival Hyperemia
- Eye Pain
- Eye Tearing
- Corneal Bleeding
- Headache
- Corneal Edema
- Photophobia
- Persistent Corneal Epithelial Defect
- Ecchymosis - Skin
- Eye Itching
Key clinical trials
- Stem Cell Therapy for Limbal Stem Cell Deficiency (PHASE1)
- Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency (PHASE1, PHASE2)
- Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops (PHASE4)
- A Study of Stem Cells Lenses in the coGVHD Subjects (EARLY_PHASE1)
- Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft (PHASE1, PHASE2)
- Ocular Biomarkers for Successful Premium Trifocal Intra-ocular Lenses Implantation
- To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies". (EARLY_PHASE1)
- Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stem Cells Lenses CI brief — competitive landscape report
- Stem Cells Lenses updates RSS · CI watch RSS
- Guangdong ProCapZoom Biosciences Co., Ltd. portfolio CI
Frequently asked questions about Stem Cells Lenses
What is Stem Cells Lenses?
Who makes Stem Cells Lenses?
What development phase is Stem Cells Lenses in?
What are the side effects of Stem Cells Lenses?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing